PRAVIGARD PAC (COPACKAGED)
LOE ApproachingNDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRAVIGARD PAC is a copackaged oral tablet combining two small-molecule components approved by Bristol Myers Squibb in June 2003. The specific indications and mechanism of action are not publicly detailed in available data, but the copackaged formulation suggests a combination therapy approach. Patient compliance and convenience are key benefits of the fixed-dose copackaged format.
LOE Approaching
With LOE approaching, commercial teams face revenue contraction and team rightsizing; career opportunities are limited to post-LOE generic transition or cost-management roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PRAVIGARD PAC offers limited career growth potential due to its LOE-approaching status and near-zero linked job openings. Career moves on this product are typically lateral or involve transition planning to post-LOE roles or other brand portfolios.
Brand ManagerField Sales Representative
Worked on PRAVIGARD PAC (COPACKAGED) at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.